KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Capital Leases (2020 - 2021)

Recursion Pharmaceuticals (RXRX) has disclosed Capital Leases for 2 consecutive years, with $9.3 million as the latest value for Q4 2021.

  • For the quarter ending Q4 2021, Capital Leases rose 244.87% year-over-year to $9.3 million, compared with a TTM value of $9.3 million through Dec 2021, up 244.87%, and an annual FY2021 reading of $9.3 million, up 244.87% over the prior year.
  • Capital Leases was $9.3 million for Q4 2021 at Recursion Pharmaceuticals, up from $3.5 million in the prior quarter.
  • Across five years, Capital Leases topped out at $9.3 million in Q4 2021 and bottomed at $2.4 million in Q2 2021.